Sarepta therapeutics announces positive data from part b of momentum, a phase 2 study of srp-5051 in patients with duchenne muscular dystrophy amenable to skipping exon 51

Cambridge, mass.--(business wire)--sarepta announces positive data from part b of momentum, a phase 2 study of srp-5051 in patients with duchenne amenable to skipping exon 51.
SRPT Ratings Summary
SRPT Quant Ranking